These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 11522649

  • 1. Role of signal transducer and activator of transcription 5 in nucleophosmin/ anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells.
    Nieborowska-Skorska M, Slupianek A, Xue L, Zhang Q, Raghunath PN, Hoser G, Wasik MA, Morris SW, Skorski T.
    Cancer Res; 2001 Sep 01; 61(17):6517-23. PubMed ID: 11522649
    [Abstract] [Full Text] [Related]

  • 2. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis.
    Slupianek A, Nieborowska-Skorska M, Hoser G, Morrione A, Majewski M, Xue L, Morris SW, Wasik MA, Skorski T.
    Cancer Res; 2001 Mar 01; 61(5):2194-9. PubMed ID: 11280786
    [Abstract] [Full Text] [Related]

  • 3. Identification of multiple SNT-binding sites on NPM-ALK oncoprotein and their involvement in cell transformation.
    Chikamori M, Fujimoto J, Tokai-Nishizumi N, Yamamoto T.
    Oncogene; 2007 May 03; 26(20):2950-4. PubMed ID: 17086210
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.
    Hsu FY, Johnston PB, Burke KA, Zhao Y.
    Cancer Res; 2006 Sep 15; 66(18):9002-8. PubMed ID: 16982741
    [Abstract] [Full Text] [Related]

  • 6. Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells.
    Ruchatz H, Coluccia AM, Stano P, Marchesi E, Gambacorti-Passerini C.
    Exp Hematol; 2003 Apr 15; 31(4):309-15. PubMed ID: 12691918
    [Abstract] [Full Text] [Related]

  • 7. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma.
    Amin HM, McDonnell TJ, Ma Y, Lin Q, Fujio Y, Kunisada K, Leventaki V, Das P, Rassidakis GZ, Cutler C, Medeiros LJ, Lai R.
    Oncogene; 2004 Jul 15; 23(32):5426-34. PubMed ID: 15184887
    [Abstract] [Full Text] [Related]

  • 8. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
    Bonvini P, Gastaldi T, Falini B, Rosolen A.
    Cancer Res; 2002 Mar 01; 62(5):1559-66. PubMed ID: 11888936
    [Abstract] [Full Text] [Related]

  • 9. Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice.
    Lange K, Uckert W, Blankenstein T, Nadrowitz R, Bittner C, Renauld JC, van Snick J, Feller AC, Merz H.
    Oncogene; 2003 Jan 30; 22(4):517-27. PubMed ID: 12555065
    [Abstract] [Full Text] [Related]

  • 10. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
    Marzec M, Kasprzycka M, Liu X, Raghunath PN, Wlodarski P, Wasik MA.
    Oncogene; 2007 Feb 08; 26(6):813-21. PubMed ID: 16909118
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice].
    Merz H, Lange K, Nadrowitz R, Uckert W, Blankenstein T, Feller AC.
    Verh Dtsch Ges Pathol; 2003 Feb 08; 87():224-31. PubMed ID: 16888916
    [Abstract] [Full Text] [Related]

  • 13. Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches.
    Wasik MA, Zhang Q, Marzec M, Kasprzycka M, Wang HY, Liu X.
    Semin Oncol; 2009 Apr 08; 36(2 Suppl 1):S27-35. PubMed ID: 19393833
    [Abstract] [Full Text] [Related]

  • 14. Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas.
    Colomba A, Courilleau D, Ramel D, Billadeau DD, Espinos E, Delsol G, Payrastre B, Gaits-Iacovoni F.
    Oncogene; 2008 Apr 24; 27(19):2728-36. PubMed ID: 17998938
    [Abstract] [Full Text] [Related]

  • 15. The oncogenic fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) induces two distinct malignant phenotypes in a murine retroviral transplantation model.
    Miething C, Grundler R, Fend F, Hoepfl J, Mugler C, von Schilling C, Morris SW, Peschel C, Duyster J.
    Oncogene; 2003 Jul 24; 22(30):4642-7. PubMed ID: 12879008
    [Abstract] [Full Text] [Related]

  • 16. Mice transgenic for NPM-ALK develop non-Hodgkin lymphomas.
    Jäger R, Hahne J, Jacob A, Egert A, Schenkel J, Wernert N, Schorle H, Wellmann A.
    Anticancer Res; 2005 Jul 24; 25(5):3191-6. PubMed ID: 16101126
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. HuR-mediated control of C/EBPbeta mRNA stability and translation in ALK-positive anaplastic large cell lymphomas.
    Bergalet J, Fawal M, Lopez C, Desjobert C, Lamant L, Delsol G, Morello D, Espinos E.
    Mol Cancer Res; 2011 Apr 24; 9(4):485-96. PubMed ID: 21343335
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.